JP2019517803A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517803A5
JP2019517803A5 JP2018565376A JP2018565376A JP2019517803A5 JP 2019517803 A5 JP2019517803 A5 JP 2019517803A5 JP 2018565376 A JP2018565376 A JP 2018565376A JP 2018565376 A JP2018565376 A JP 2018565376A JP 2019517803 A5 JP2019517803 A5 JP 2019517803A5
Authority
JP
Japan
Prior art keywords
genetically modified
nucleic acid
item
exogenous nucleic
modified non
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517803A (ja
JP7519660B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/037566 external-priority patent/WO2017218714A1/en
Publication of JP2019517803A publication Critical patent/JP2019517803A/ja
Publication of JP2019517803A5 publication Critical patent/JP2019517803A5/ja
Priority to JP2021212142A priority Critical patent/JP2022031487A/ja
Priority to JP2022129299A priority patent/JP2022160703A/ja
Application granted granted Critical
Publication of JP7519660B2 publication Critical patent/JP7519660B2/ja
Priority to JP2024154774A priority patent/JP2024178220A/ja
Priority to JP2025015908A priority patent/JP2025076449A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565376A 2016-06-14 2017-06-14 疾患を処置するための遺伝子改変された細胞、組織、および臓器 Active JP7519660B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021212142A JP2022031487A (ja) 2016-06-14 2021-12-27 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2022129299A JP2022160703A (ja) 2016-06-14 2022-08-15 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2024154774A JP2024178220A (ja) 2016-06-14 2024-09-09 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2025015908A JP2025076449A (ja) 2016-06-14 2025-02-03 疾患を処置するための遺伝子改変された細胞、組織、および臓器

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350048P 2016-06-14 2016-06-14
US62/350,048 2016-06-14
PCT/US2017/037566 WO2017218714A1 (en) 2016-06-14 2017-06-14 Genetically modified cells, tissues, and organs for treating disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021212142A Division JP2022031487A (ja) 2016-06-14 2021-12-27 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2022129299A Division JP2022160703A (ja) 2016-06-14 2022-08-15 疾患を処置するための遺伝子改変された細胞、組織、および臓器

Publications (3)

Publication Number Publication Date
JP2019517803A JP2019517803A (ja) 2019-06-27
JP2019517803A5 true JP2019517803A5 (https=) 2020-07-27
JP7519660B2 JP7519660B2 (ja) 2024-07-22

Family

ID=60663278

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018565376A Active JP7519660B2 (ja) 2016-06-14 2017-06-14 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2021212142A Pending JP2022031487A (ja) 2016-06-14 2021-12-27 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2022129299A Pending JP2022160703A (ja) 2016-06-14 2022-08-15 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2024154774A Pending JP2024178220A (ja) 2016-06-14 2024-09-09 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2025015908A Pending JP2025076449A (ja) 2016-06-14 2025-02-03 疾患を処置するための遺伝子改変された細胞、組織、および臓器

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021212142A Pending JP2022031487A (ja) 2016-06-14 2021-12-27 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2022129299A Pending JP2022160703A (ja) 2016-06-14 2022-08-15 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2024154774A Pending JP2024178220A (ja) 2016-06-14 2024-09-09 疾患を処置するための遺伝子改変された細胞、組織、および臓器
JP2025015908A Pending JP2025076449A (ja) 2016-06-14 2025-02-03 疾患を処置するための遺伝子改変された細胞、組織、および臓器

Country Status (8)

Country Link
US (1) US20190335726A1 (https=)
EP (1) EP3468356A4 (https=)
JP (5) JP7519660B2 (https=)
KR (2) KR20230110373A (https=)
CN (2) CN109640645B (https=)
AU (1) AU2017285224B2 (https=)
CA (1) CA3027428A1 (https=)
WO (1) WO2017218714A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
SG11201602232UA (en) 2013-09-24 2016-04-28 Giner Inc System for gas treatment of a cell implant
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
WO2018075830A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
AU2017361260B2 (en) 2016-11-15 2023-06-08 Giner, Inc. Percutaneous gas diffusion device suitable for use with a subcutaneous implant
CN110831656A (zh) 2017-05-04 2020-02-21 吉纳生命科学公司 稳健的可植入气体递送装置和方法、系统以及包括该装置的装置
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
EP3866815B1 (en) * 2018-10-19 2024-05-01 Regents Of The University Of Minnesota Transplant tolerance induction with carbodiimide treated tolerizing vaccine
EP3760718A1 (en) * 2019-07-04 2021-01-06 Medizinische Hochschule Hannover Tissue for use as allogeneic or xenogeneic transplant and method for its production
CN111264469B (zh) * 2020-02-27 2022-03-25 西安交通大学医学院第一附属医院 一种基因免疫诱导的甲状腺相关性眼病动物模型的构建方法及雷帕霉素类药物的应用
US20230123863A1 (en) * 2020-06-30 2023-04-20 National Yang-Ming University A glia cell and neuron co-culture system and method
CN111500693B (zh) * 2020-07-02 2020-09-22 中南大学 检测巨噬细胞中rfx1表达水平的试剂在制备巨噬细胞分型检测制剂中的应用
WO2023015307A1 (en) * 2021-08-06 2023-02-09 Rutgers, The State University Of New Jersey Method for producing genetically modified cells
US20240358761A1 (en) * 2021-08-11 2024-10-31 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
CN114958768B (zh) * 2022-06-02 2023-03-24 健颐生物科技发展(山东)有限公司 Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
WO2026039661A1 (en) * 2024-08-15 2026-02-19 Regeneron Pharmaceuticals, Inc. Non-human animals with humanized fc epsilon receptors that lack functional alpha-1, 3-galactosyltransferase (ggta1)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156306A (en) * 1994-08-17 2000-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pancreatic β-cells for allogeneic transplantation without immunosuppression
US5770201A (en) * 1994-12-23 1998-06-23 Rijsuniversiteit Te Leiden HA-2 antigenic peptide
JPH11510698A (ja) * 1995-08-04 1999-09-21 ザ ジェネラル ホスピタル コーポレイション トランスジェニックブタ及びヒトｈｌａ遺伝子を有するブタ細胞
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
FR2760023B1 (fr) * 1997-02-21 2004-05-07 Commissariat Energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications
WO2002064748A2 (en) * 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
CN1377225A (zh) * 1999-09-13 2002-10-30 马萨诸塞大学 使用来自分化细胞的供体细胞或细胞核克隆猪以及多能猪的生成
KR100417566B1 (ko) * 1999-11-19 2004-02-05 한국생명공학연구원 체세포 핵치환 복제수정란의 대량생산방법
AU2001297523B2 (en) * 2000-11-17 2007-01-18 Sab, Llc Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
AU2002357110A1 (en) * 2001-12-07 2003-07-09 The Ohio State University Research Foundation Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder
US20050123525A1 (en) * 2003-11-13 2005-06-09 Ulrich Martin Composition and method for inducing immune tolerance towards cell, tissue and/or organ transplants
KR20090068646A (ko) * 2007-12-24 2009-06-29 (주)엠젠 Ｈｌａ-ｇ 유전자 및 ｄａｆ 유전자를 발현하는 형질전환복제 돼지 및 그의 제조 방법
KR20100022684A (ko) * 2008-08-20 2010-03-03 (주)엠젠 세 개의 유전자를 발현하는 복합형질전환 복제 돼지 및 그의 제조 방법
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2184070A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
EP2184297A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
CN102300578A (zh) * 2008-12-01 2011-12-28 延寿有限责任公司 用于改变健康、安康和寿命的方法和组合物
JP5940977B2 (ja) * 2009-08-11 2016-06-29 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的改変によるホモ接合生物
ES2767881T3 (es) * 2009-08-14 2020-06-18 Revivicor Inc Cerdos multi-transgénicos para el tratamiento de diabetes
US8734786B2 (en) * 2009-09-16 2014-05-27 Northwestern University Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection
US20130177577A1 (en) * 2010-07-12 2013-07-11 Dana-Farber Cancer Institute, Inc. Nlrc5 as a target to intervene mhc class 1-mediated immune responses
WO2012031008A2 (en) * 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012072096A1 (en) * 2010-12-03 2012-06-07 Biontech Ag Method for cellular rna expression
ES2680636T3 (es) * 2011-02-14 2018-09-10 Revivicor Inc. Cerdos genéticamente modificados para xenotrasplante de xenoinjertos vascularizados y derivados de los mismos
MX363013B (es) * 2011-02-25 2019-03-04 Recombinetics Inc Animales genéticamente modificados y métodos para su obtención.
CN102911270A (zh) * 2011-08-05 2013-02-06 浙江大学 一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法
DK2830662T3 (da) * 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
WO2013188358A1 (en) * 2012-06-12 2013-12-19 The General Hospital Corporation Miniature swine transgenic for one or more coagulation factors
SG11201500799YA (en) * 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
US20140115728A1 (en) * 2012-10-24 2014-04-24 A. Joseph Tector Double knockout (gt/cmah-ko) pigs, organs and tissues
CN104046593A (zh) * 2013-03-14 2014-09-17 浙江大学 一种低免疫原性的人细胞及其制备方法
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP2016538001A (ja) * 2013-11-28 2016-12-08 ホライズン・ジェノミクス・ゲーエムベーハー 体細胞半数体ヒト細胞株
WO2015184259A1 (en) * 2014-05-30 2015-12-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods to treat latent viral infections
SI3161128T1 (sl) * 2014-06-26 2019-02-28 Regeneron Pharmaceuticals, Inc. Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe
CN105586389A (zh) * 2014-10-21 2016-05-18 天津华大基因科技有限公司 试剂盒及其在检测遗传性骨病基因中的用途
CA2965550A1 (en) * 2014-10-22 2016-04-28 Indiana University Research & Technology Corporation Triple transgenic pigs suitable for xenograft
CN116059378A (zh) * 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN104789592A (zh) * 2015-03-19 2015-07-22 中国食品药品检定研究院 一种制备α-1,3GT基因敲除的非人哺乳动物的方法及应用

Similar Documents

Publication Publication Date Title
JP2019517803A5 (https=)
CN109640645B (zh) 用于治疗疾病的遗传修饰的细胞、组织和器官
US20210085720A1 (en) Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
JP6830437B2 (ja) 疾患を処置するための遺伝子改変された細胞、組織および臓器
Müller et al. Transgenic pigs carrying cDNA copies encoding the murine Mx1 protein which confers resistance to influenza virus infection
JP2018500897A5 (https=)
EP3058819B1 (en) Hla class i expressing non-human animal
US7547522B2 (en) Method to enrich for α(1,3)-galactosyltransferase null pig cells
Perota et al. Generation of cattle knockout for galactose‐α1, 3‐galactose and N‐glycolylneuraminic acid antigens
Magliocca et al. Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression
Jeong et al. Production of multiple transgenic Yucatan miniature pigs expressing human complement regulatory factors, human CD55, CD59, and H-transferase genes
JP6942466B2 (ja) 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
US12448437B2 (en) Transplant tolerance induction with carbodiimide treated tolerizing vaccine
KR20220132521A (ko) 변형된 줄기세포 및 이의 사용 방법
WO2020158924A1 (ja) 母児間免疫寛容を誘導する方法
JP2020535834A (ja) 遺伝子修飾されたベータ細胞による糖尿病の治療
JP5745419B2 (ja) 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法
US20230374448A1 (en) Hypoimmunogenic Cells and Methods and Compositions for Their Production
Pilunov et al. Modification of Cytotoxic Lymphocytes with T Cell Receptor Specific for Minor Histocompatibility Antigen ACC-1Y
CN1396832A (zh) 抵制抗供体免疫的移植前适应器官
EP3510861A2 (en) Hypoallergenic food and medical products from genome edited livestock
US20240294869A1 (en) Pig xenotransplants into humans without chronic immunosuppression
KR20260050358A (ko) 유전자 변형된 돼지 세포, 유전자 변형된 돼지 및 이의 생산 방법
リアン クイーン Studies on genome editing techniques using CRISPR/Cas9 in porcine embryos
WO2025219520A1 (en) MODIFIED HUMAN T CELL WITH A REDUCED HLA-Ia REPERTOIRE AND METHOD OF PRODUCTION